A Phase II Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer.

This document provides information about a clinical trial for the treatment of small cell lung carcinoma. The trial involves the use of a drug called Adebrelimab, as well as chemotherapy and radiation therapy. The trial is currently recruiting participants, with an estimated enrollment of 62 individuals. The study is being conducted in China and is expected to be completed by September 30, 2026. The eligibility criteria for participants are outlined, and the responsible party for the trial is Nanfang Hospital, Southern Medical University. [Extracted from the article]